Tofacitinib
- Product NDC
- 84677-055
- Requested package NDC
- 84677-055-60
- 11-digit product format
- 846770055
- Labeler code
- 84677
- Product ID
- 84677-055_58f22511-eebf-fdbd-e063-6294a90adb8e
- Type
- HUMAN PRESCRIPTION DRUG
- Nonproprietary name
- tofacitinib
- Dosage form
- TABLET, FILM COATED
- Route
- ORAL
- Application
- ANDA218096
- Marketing category
- ANDA
- Marketing start
- 2026-06-01
- Substance
- TOFACITINIB
- Active strength
- 10 mg/1
- Pharmacologic classes
- Janus Kinase Inhibitor [EPC]; Janus Kinase Inhibitors [MoA]
- Listing certified through
- 2027-12-31
- Current FDA listing
- Yes
Orange Book products#
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| A218096-001 | TOFACITINIB CITRATE | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-03 | |
| A218096-002 | TOFACITINIB CITRATE | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-03 |
Therapeutic equivalence codes#
| Application-product | TE code |
|---|---|
| A218096-001 | AB |
| A218096-002 | AB |
Observed Orange Book product history#
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A218096-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-03 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | A218096-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-03 | caaa826d4ba7… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218096-001 | TOFACITINIB CITRATE | EQ 5MG BASE | TABLET / ORAL | AB | 2026-06-03 | a50c72e98297… | |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218096-002 | TOFACITINIB CITRATE | EQ 10MG BASE | TABLET / ORAL | AB | 2026-06-03 | a50c72e98297… |
Observed Orange Book normalized TE history#
| Captured | Edition | Application-product | TE code | Order | Source SHA-256 |
|---|---|---|---|---|---|
| 2026-08-18 06:07:40 | 2026-07 | A218096-001 | AB | 1 | caaa826d4ba7… |
| 2026-08-18 06:07:40 | 2026-07 | A218096-002 | AB | 1 | caaa826d4ba7… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218096-001 | AB | 1 | a50c72e98297… |
| 2026-07-26 02:55 UTC · 3 captures of this ZIP | 2026-06 | A218096-002 | AB | 1 | a50c72e98297… |
Additional Listing Data#
- Finished product
- Yes
- Brand name base
- Tofacitinib
- Listing expiration
- 2027-12-31
Active Ingredients#
| Ingredient | Strength |
|---|---|
| TOFACITINIB | 10 mg/1 |
openFDA label cross-check#
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| Tofacitinib | TOFACITINIB | Golden State Medical Supply, Inc. | 58f22c41-87d2-e745-e063-6394a90a962e | 2026-08-13 | Boxed warning, Warnings, Adverse reactions | 218096 ANDA218096 84677-055-60 84677-055 84677005560 |
| Tofacitinib | TOFACITINIB | Apotex Corp. | 7d4f5cfa-35a8-1458-a609-f6b417946abb | 2026-08-04 | Boxed warning, Warnings, Adverse reactions | 218096 ANDA218096 |
Packages#
| Package NDC | 11-digit format | Description | Marketing start | Sample | Status |
|---|---|---|---|---|---|
| 84677-055-60 | 84677005560 | 60 TABLET, FILM COATED in 1 BOTTLE (84677-055-60) | 2026-06-01 | 0 | Current |